{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.5","upperLimit":"98.2","value":"96.3"},{"groupId":"OG001","lowerLimit":"92.1","upperLimit":"99.8","value":"98.9"},{"groupId":"OG002","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG003","lowerLimit":"69.2","upperLimit":"93.8","value":"85.8"},{"groupId":"OG004","lowerLimit":"79.7","upperLimit":"96.6","value":"91.8"},{"groupId":"OG005","lowerLimit":"75.7","upperLimit":"99.4","value":"96.2"},{"groupId":"OG006","lowerLimit":"67.2","upperLimit":"89.8","value":"81.3"},{"groupId":"OG007","lowerLimit":"53.0","upperLimit":"85.4","value":"72.9"},{"groupId":"OG008","lowerLimit":"27.4","upperLimit":"59.9","value":"44.3"},{"groupId":"OG009","lowerLimit":"21.7","upperLimit":"56.5","value":"39.3"},{"groupId":"OG010","lowerLimit":"5.2","upperLimit":"33.7","value":"16.7"}]}],"title":"Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.7","upperLimit":"92.1","value":"88.2"},{"groupId":"OG001","lowerLimit":"91.0","upperLimit":"99.4","value":"97.7"},{"groupId":"OG002","lowerLimit":"20.4","upperLimit":"96.9","value":"80.0"},{"groupId":"OG003","lowerLimit":"62.0","upperLimit":"89.8","value":"79.7"},{"groupId":"OG004","lowerLimit":"69.3","upperLimit":"91.3","value":"83.3"},{"groupId":"OG005","lowerLimit":"72.6","upperLimit":"98.0","value":"92.3"},{"groupId":"OG006","lowerLimit":"57.6","upperLimit":"83.1","value":"72.7"},{"groupId":"OG007","lowerLimit":"39.2","upperLimit":"74.3","value":"59.0"},{"groupId":"OG008","lowerLimit":"24.9","upperLimit":"57.0","value":"41.3"},{"groupId":"OG009","lowerLimit":"11.1","upperLimit":"41.8","value":"25.0"},{"groupId":"OG010","lowerLimit":"1.4","upperLimit":"23.3","value":"8.3"}]}],"title":"Year 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.8","upperLimit":"88.7","value":"84.1"},{"groupId":"OG001","lowerLimit":"83.9","upperLimit":"97.1","value":"93.0"},{"groupId":"OG002","lowerLimit":"20.4","upperLimit":"96.9","value":"80.0"},{"groupId":"OG003","lowerLimit":"44.5","upperLimit":"80.9","value":"66.1"},{"groupId":"OG004","lowerLimit":"69.3","upperLimit":"91.3","value":"83.3"},{"groupId":"OG005","lowerLimit":"62.9","upperLimit":"95.6","value":"86.5"},{"groupId":"OG006","lowerLimit":"54.7","upperLimit":"81.1","value":"70.1"},{"groupId":"OG007","lowerLimit":"25.4","upperLimit":"63.0","value":"45.1"},{"groupId":"OG008","lowerLimit":"24.9","upperLimit":"57.0","value":"41.3"},{"groupId":"OG009","lowerLimit":"5.6","upperLimit":"32.9","value":"16.7"},{"groupId":"OG010","lowerLimit":"1.4","upperLimit":"23.3","value":"8.3"}]}],"title":"Year 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.7","upperLimit":"86.6","value":"81.5"},{"groupId":"OG001","lowerLimit":"83.9","upperLimit":"97.1","value":"93.0"},{"groupId":"OG002","lowerLimit":"20.4","upperLimit":"96.9","value":"80.0"},{"groupId":"OG003","lowerLimit":"44.5","upperLimit":"80.9","value":"66.1"},{"groupId":"OG004","lowerLimit":"63.1","upperLimit":"89.0","value":"79.3"},{"groupId":"OG005","lowerLimit":"62.9","upperLimit":"95.6","value":"86.5"},{"groupId":"OG006","lowerLimit":"48.6","upperLimit":"78.3","value":"65.7"},{"groupId":"OG007","lowerLimit":"25.4","upperLimit":"63.0","value":"45.1"},{"groupId":"OG008","lowerLimit":"2.0","upperLimit":"53.2","value":"20.7"},{"groupId":"OG009","lowerLimit":"5.6","upperLimit":"32.9","value":"16.7"},{"groupId":"OG010","lowerLimit":"1.4","upperLimit":"23.3","value":"8.3"}]}],"title":"Year 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.6","upperLimit":"85.9","value":"80.6"},{"groupId":"OG001","lowerLimit":"76.6","upperLimit":"94.5","value":"88.4"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Year 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"49"},{"groupId":"OG007","value":"30"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"28"},{"groupId":"OG010","value":"24"}],"units":"Participants"}],"description":"OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death or date of last contact for those censored.\n\nNA = not estimable. One year = 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG006","title":"Bosutinib 500 mg, AP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG007","title":"Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG008","title":"Bosutinib 500 mg, BP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG009","title":"Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG010","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"NUMBER","populationDescription":"All-treated population included all enrolled participants who received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"Years 1, 2, 3, 4, and 5 (CP2L only)","title":"Kaplan-Meier Estimate of Overall Survival (OS) - Part 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}